Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)Depreciation ExpenseEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

NRX Pharmaceuticals (NRXP) Cost of Revenue (2025)

NRX Pharmaceuticals (NRXP) has disclosed Cost of Revenue for 1 consecutive years, with $408000.0 as the latest value for Q4 2025.

  • Quarterly Cost of Revenue changed N/A to $408000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $505000.0 through Dec 2025, changed N/A year-over-year, with the annual reading at $505000.0 for FY2025, N/A changed from the prior year.
  • Cost of Revenue for Q4 2025 was $408000.0 at NRX Pharmaceuticals, up from $97000.0 in the prior quarter.
  • The five-year high for Cost of Revenue was $408000.0 in Q4 2025, with the low at $97000.0 in Q3 2025.